← Back to headlines
BioNTech Rally on Moderna Trial Win Expected to Fade, Leerink Predicts
Leerink analysts suggest that BioNTech's recent stock rally, spurred by a Moderna trial win, is likely to be short-lived.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
